This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cardiologists have a wide selection of TAVR valves to choose from, and a new study pitting the top three second generation devices against each other suggests theres not much difference in the long run. So far, we havent known the long-term clinical outcomes of second-generation devices for TAVR beyond five years after implantation.
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Reardon, M.D., Grubb, M.D., 1 Herrmann H.
The optimal management of concomitant chronic obstructive coronary artery disease (CAD) in transcatheter aortic valve replacement (TAVR) recipients remains a debated topic. While some advocate for pre-TAVR percutaneous coronary intervention, others adopt an expectant approach. Original article: Persits I et al.
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. Perivalvular thrombus has also been reported. Original article: Choi Y et al.
(MedPage Today) -- NEW YORK CITY -- Researchers eked out evidence of a small clinical benefit with the Sentinel cerebral embolic protection (CEP) device in transcatheter aortic valve replacement (TAVR) -- and pointed to the patients more likely.
Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported it has reached a significant milestone of performing over 5,000 transcatheter aortic valve replacement (TAVR) procedures, the first in New Jersey and among the first to accomplish this in the United States. million people.
By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. The research team followed these patients for a median time of 2.4 years after TAVR and 4.9 She added that her research group has expanded their analysis to include a multi-state registry for better comparison of the two procedures. “As
The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first transcatheter aortic valve replacement (TAVR) in 2002, as well as the first transcatheter mitral commissurotomy in 1995 and the first balloon aortic valvuloplasty in 1986. He passed away Feb. 16, 2024 at the age of 79.
Better Understanding TAVR While TAVR has earned its reputation for safety and efficacy, several late breaking trials helped clarify ways to improve it and even complicate it. Thats an important one to answer for clinicians, researchers, and businessmen alike whether it’s for imaging, drugs, or devices.
milla1cf Mon, 01/29/2024 - 11:00 January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio. The findings underscore the escalating need for both aortic and non-aortic valve cardiac surgeries following TAVR.
Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during a Late-Breaking Clinical Trial session at ACC.25 25 in Chicago and simultaneously published in JACC.
Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates. The post SAVR’s Value in the TAVR Era appeared first on Cardiac Wire.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
Resource SAVR After TAVR Risk Calculator kchalko Fri, 04/12/2024 - 13:53 SAVR after previous TAVR is the fastest-growing cardiac surgery procedure in the U.S. The majority of patients require explant of their TAVR device and SAVR with significantly increased risk of operative mortality and stroke.
However, with the compelling evidence on the safety and efficacy of transcatheter aortic valve replacement (TAVR), it has become the gold standard treatment option for many patients with symptomatic severe AS. Therefore, alternative TAVR approaches have gained increasing utility in cases where transfemoral access is unfavorable.
The first cases were performed by Dr. Tamim Nazif , Director of Clinical Research, Dr. Susheel Kodali , Professor of Medicine and Director of the Structural Heart and Valve Center , and Dr. Isaac George , Surgical Director of the Heart Valve Center. Teleflex received 510(k) clearance from the U.S. Testing completed by Teleflex.
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.
HonorHealth Research Institute Study Uses New Programing for Pacemakers to Control High Blood Pressure Without Additional Drugs 6. Atlantic Health System’s Morristown Medical Center Tops 5,000 TAVR Procedures 8. In Memoriam: Prolific Philanthropist Ann Lurie, Namesake of the Ann and Robert H Lurie Children’s Hospital of Chicago 5.
Abstract Transcatheter aortic valve replacement (TAVR) often leads to conduction abnormalities, necessitating pacemaker implantation. Prevention focuses on tailoring TAVR to individual electrophysiological and anatomical profiles. Procedural factors like transfemoral access and self-expandable valves also increase this risk.
All patients were pre-TAVR assessed by transthoracic echocardiography and computed tomography of the aortic valve (AV) and relevant left cardiac and vascular anatomy. Nanjing) to evaluate its safety and efficacy.Methods130 high risk patients with symptomatic severe AS from 11 institutions were treated with the novel Xcor system.
Widely recognized for pioneering innovative concepts and techniques in TAVR, Tang has set contemporary standards in the field. His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease.
Transcatheter aortic valve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.
Transcatheter aortic valve replacement (TAVR) has increasingly become a safe, feasible, and widely accepted alternative surgical treatment for patients with severe symptomatic aortic stenosis.
Researchers examined STS registry data on ~109k patients ages 40 to 75 years who received isolated bioprosthetic (94k) or mechanical (15k) AVR over 11 years and found that mechanical valve use decreased by about half (from 20% in 2008 to below 10% in 2019).
Glycemic control is critical for managing transcatheter aortic valve replacement (TAVR) patients, especially those in intensive care units (ICUs). Emerging metrics such as the hemoglobin glycation index (HGI),
Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.
TAVR in heart failure. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.
Only the transfemoral transcatheter aortic valve replacement (TAVR) approach was associated with the prevention of POAF and was supported by convincing evidence from meta-analyses of observational data. Further research is needed to assess the potential role of statins, glucocorticoids and colchicine in the prevention of POAF.
Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. Conclusion Prior CABG may positively affect mid-term TAVR outcomes for aortic stenosis compared with no CAD when adjusted for other comorbidities.
Widely recognized for pioneering innovative concepts and techniques in TAVR, Tang has set contemporary standards in the field. His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease.
Five highly-anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73 rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA. ET Murphy Ballroom 4 ACC.24
Additionally, considering the recent FDA recall of Impella devices in patients who have had transcatheter aortic valve replacement (TAVR) procedures due to the risk of motor damage after contact with TAVR stents, this case calls attention to a need for further research of the use and safety of Impella devices in patients with non-native aortic valves. (..)
It seems even interventional cardiologists arent immune to the Weekend Effect as a recent study suggests patients admitted on weekends for TAVR procedures face significantly higher risks. The post The Weekend Effect Touches TAVR Too appeared first on Cardiac Wire.
Bucshon and Schrier on this important bill which will not only have a measurable impact on clinical research, but also make a difference in cardiovascular clinicians’ efforts to transform cardiovascular care and improve heart health.” The ACC looks forward to working with Reps. Learn more at sts.org. For more, visit acc.org.
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%
Transcatheter aortic valve replacement (TAVR) has emerged as the preferred treatment for older patients suffering from severe aortic valve stenosis, surpassing the annual patient count of those opting for surgical aortic valve replacement. Notably, TAVR demonstrates lower rates of periprocedural major bleeding compared to traditional surgery.
TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. The DEDICATE-DZHK6 trial compared TAVR vs. SAVR in 1,414 patients who underwent valve replacement procedures at 38 centers in Germany.
Within the realm of transcatheter aortic valve replacement (TAVR), stroke emerges as a recognized adverse event, manifesting at various stages during and after the procedure. Previous studies extensively delved into short-term incidence, trends, and clinical outcomes related to TAVR-associated stroke. female) were included. at 5 years.
The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. The trial enrolled 716 patients who underwent TAVR at 83 international sites in North America, Europe and the Middle East.
The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. Sinai Hospital (New York, NY).
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.
Our research underscores that for patients with an age threshold of 60 years, mechanical valves confer a significant survival advantage. This data will help patients and providers make more informed choices about their care. Adult Cardiac All Members Clinical Decision-Making Patient Outcomes Quality Improvement
In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 3.5%, p=0.80) between the redo-TAVR and native-TAVR populations.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content